Sandip Kapadia
2016 - Intercept Pharmaceuticals
In 2016, Sandip Kapadia earned a total compensation of $4.2M as Chief Financial Officer at Intercept Pharmaceuticals.
Compensation breakdown
| Bonus | $75,000 |
|---|---|
| Non-Equity Incentive Plan | $183,000 |
| Option Awards | $1,559,019 |
| Salary | $200,000 |
| Stock Awards | $2,195,400 |
| Other | $7,057 |
| Total | $4,219,476 |
Kapadia received $2.2M in stock awards, accounting for 52% of the total pay in 2016.
Kapadia also received $75K in bonus, $183K in non-equity incentive plan, $1.6M in option awards, $200K in salary and $7.1K in other compensation.
Rankings
In 2016, Sandip Kapadia's compensation ranked 2,056th out of 14,075 executives tracked by ExecPay. In other words, Kapadia earned more than 85.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,056 out of 14,075 | 85th |
Division Manufacturing | 706 out of 5,486 | 87th |
Major group Chemicals And Allied Products | 204 out of 1,900 | 89th |
Industry group Drugs | 147 out of 1,543 | 91st |
Industry Pharmaceutical Preparations | 119 out of 1,173 | 90th |
Source: SEC filing on April 27, 2018.
Kapadia's colleagues
We found two more compensation records of executives who worked with Sandip Kapadia at Intercept Pharmaceuticals in 2016.
News
Intercept Pharmaceuticals CEO Jerome Durso's 2021 pay jumps 101% to $7.9M
May 2, 2022
Harmony Biosciences Holdings CFO Sandip Kapadia's 2021 pay jumps 171% to $6.2M
April 8, 2022
Intercept Pharmaceuticals CEO Mark Pruzanski's 2020 pay slips 3% to $6.4M
April 27, 2021
Intercept Pharmaceuticals CEO Mark Pruzanski's 2019 pay jumps 46% to $6.6M
April 29, 2020
Intercept Pharmaceuticals CEO Mark Pruzanski's 2018 pay falls 26% to $4.5M
April 30, 2019